Home

Thomas J. Lynch Jr.

CIK 1474056 · EVP & Chief Scientific Officer · last filed 2026-06-25

Thomas J. Lynch Jr. is an EVP & Chief Scientific Officer who has filed 34 SEC Form 4 insider transactions across 3 companies since 2009. The most recent filing, for FHTX, was dated Jun 25, 2026. Across all open-market trades the lifetime net is −$335.2K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.5M across reported positions. 26 SEC filings were submitted jointly with MYERS SQUIBB CO BRISTOL.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.54M

Companies

3

Total Filings

34

Lifetime Open-Market Net

-$335.2K

Filer Profile

Reported Address
800 HOWARD AVENUE
YALE PHYSICIANS BUILDING, 2ND FLOOR
NEW HAVEN, CT 06519
Related Filers
MYERS SQUIBB CO BRISTOL — 26 joint filings, latest 2019-04-05
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
FHTX Director — $4.83 — $0 5 2026-06-25
BMY EVP & Chief Scientific Officer 23,868 $64.61 $1.54M -$335.2K 24 2019-04-05
INFINITY PHARMACEUTICALS, INC. (INFI) Delisted Director — $0.04 — $0 5 2013-06-13

Recent Filings

34 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-25 FHTX Grant (A) — $0 EDGAR
2025-06-17 FHTX Grant (A) — $0 EDGAR
2024-06-28 FHTX Grant (A) — $0 EDGAR
2023-06-22 FHTX Grant (A) — $0 EDGAR
2022-10-31 FHTX Grant (A) — $0 EDGAR
2019-04-05 BMY Mixed +4,650 -$289.3K EDGAR
2019-03-13 BMY Mixed +2,094 -$122.5K EDGAR
2018-04-05 BMY Mixed +6,228 -$444.9K EDGAR
2018-03-13 BMY Grant (A) — $0 EDGAR
2017-12-13 BMY Sell (S) −5,300 -$335.2K EDGAR
Showing 1–10 of 34
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.